drugset
drugset / Trial / NCT04032821

To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy Subjects

NCT04032821 ↗

Phase 1 Completed 16 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

To evaluate the safety and tolerability of food to Alkotinib Capsules in healthy subjects

Timeline

Start
2019-11-20
Primary completion
2019-12-16
Completion
2019-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Alkotinib Unknown 300 mg —

Indications

non-small cell lung carcinoma